林俊超;梁洁;吴开春;

• 1:空军军医大学西京医院消化内科

摘要(Abstract)：

生物制剂与小分子药物作为治疗炎症性肠病的较新方法在国内外临床实践中日益增多,人们对其的认识和接受程度亦日渐加深。国内外研究显示,生物制剂与小分子药物可实现黏膜愈合,减少相关并发症和疾病复发,改善患者生活质量,降低住院率和外科手术率。随着生物制剂种类的增多和临床研究的不断深入,疗效更佳的新一代药物不断出现,本文就目前临床和临床试验进行中的治疗炎症性肠病的生物制剂和小分子药物进行综述,为炎症性肠病患者的个体化治疗提供帮助。

关键词(KeyWords)： 炎症性肠病;生物制剂;小分子药物;治疗效果;安全性

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金国家重大科研仪器研制项目(81627807)

作者(Authors): 林俊超;梁洁;吴开春;

参考文献(References)：

• [1]RODRíGUEZ-REYNA T S,MARTíNEZ-REYES C,YAMAMOTO-FURUSHO J K.Rheumatic manifestations of inflammatory bowel disease[J].World J Gastroenterol,2009,15(44):5517-5524.
• [2]MANNON P J,FUSS I J,MAYER L.Anti-IL-12 Crohn's Disease Study Group.Anti-interleukin-12 antibody for active Crohn's disease[J].N Engl J Med,2004,351(20):2069-2079.
• [3]ANDOU A,HISAMATSU T,OKAMOTO S,et al.Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages[J].Gastroenterology,2009,136(2):564-574.e2.
• [4]NOBUHIKO K,TADAKAZU H,SUSUMU O,et al.Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-γ axis[J].J Clin Invest,2008,118(6):2269-2280.
• [5]XIAO S,JIN H,KORN T,et al.Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression[J].J Immunol,2008,181(4):2277-2284.
• [6]BURGER D,TRAVIS S.Conventional medical management of inflammatory bowel disease[J].Gastroenterology,2011,140(6):1827-1837.e2.
• [7]SANDBORN W J.Current directions in IBD therapy:what goals are feasible with biological modifiers?[J].Gastroen-tero-logy,2008,135(5):1442-1447.
• [8]KATZ S.Update in medical therapy of ulcerative colitis:a practical approach[J].J Clin Gastroenterol,2002,34(4):397-407.
• [9]KIM D H,CHEON J H.Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies[J].Immune Netw,2017,17(1):25-40.
• [10]RODA G,JHARAP B,NEERAJ N,et al.Loss of Response to Anti-TNFs:Definition,Epidemiology and Management[J].Clin Transl Gastroenterol,2016,7(1):e135.
• [11]GISBERT J P,CHAPARRO M.Predictors of Primary Response to Biologic Treatment[Anti-TNF,Vedolizumab,and Ustekin-umab]in Patients With Inflammatory Bowel Disease:From Basic Science to Clinical Practice[J].J Crohns Colitis,2020,14(5):694-709.
• [12]SABINO J,VERSTOCKT B,VERMEIRE S,et al.New biologics and small molecules in inflammatory bowel disease:an update[J].Therap Adv Gastroenterol,2019,12:1756284819853208.
• [13]SANDBORN W J,SU C,SANDS B E,et al.Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis[J].N Engl J Med,2017,376(18):1723-1736.
• [14]XIONG Y J,DENG Z B,LIU J N,et al.Enhancement of epith-elial cell autophagy induced by sinensetin alleviates epithe-lial barrier dysfunction in colitis[J].Pharmacol Res,2019,148:104461.
• [15]FENG P P,FANG X S,ZHAO S,et al.Salvianolic acid B decre-ases interleukin-1β-induced colitis recurrence in mice[J].Chin Med J (Engl),2020,133(12):1436-1444.
• [16]REKI? D,REYNOLDS K S,ZHAO P,et al.Clinical Drug-Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access[J].J Pharm Sci,2017,106(9):2214-2218.
• [17]KAMADA N,HISAMATSU T,OKAMOTO S,et al.Abnor-mally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria[J].J Immunol,2005,175(10):6900-6908.
• [18]BAI A P,OUYANG Q.Probiotics and inflammatory bowel diseases[J].Postgrad Med J,2006,82(968):376-382.
• [19]ABRAHAM C,CHO J H.Inflammatory bowel disease[J].N Engl J Med,2009,361(21):2066-2078.
• [20]CHEON J H.Genetics of inflammatory bowel diseases:a comparison between Western and Eastern perspectives[J].J Gastroenterol Hepatol,2013,28(2):220-226.
• [21]LICHTENSTEIN L,RON Y,KIVITY S,et al.Infliximab-Related Infusion Reactions:Systematic Review[J].J Crohns Colitis,2015,9(9):806-815.
• [22]SHIVAJI U N,SHARRATT C L,THOMAS T,et al.Review article:managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease[J].Aliment Pharmacol Ther,2019,49(6):664-680.
• [23]COLOMBEL J F,SANDBORN W J,RUTGEERTS P,et al.Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease:the CHARM trial[J].Gastroenterology,2007,132(1):52-65.
• [24]SANDBORN W J,SCHREIBER S,FEAGAN B G,et al.Certolizumab pegol for active Crohn's disease:a placebo-controlled,randomized trial[J].Clin Gastroenterol Hepatol,2011,9(8):670-678.e3.
• [25]FARKAS K,LAKATOS P L,NAGY F.Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy[J].Scand J Gastroenterol,2013,48(12):1394-1398.
• [26]CHOY E H,HAZLEMAN B,SMITH M,et al.Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis:a phase Ⅱ double-blinded,rand-omi-zed,dose-escalating trial[J].Rheumatology (Oxford),2002,41(10):1133-1137.
• [27]HARRIS M S,HARTMAN D,LEMOS B R,et al.AVX-470,an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis:Results of a First-in-Human Trial[J].J Crohns Colitis,2016,10(6):631-640.
• [28]YOSHIMURA N,WATANABE M,MOTOYA S,et al.Safety and Efficacy of AJM300,an Oral Antagonist of α4 Integrin,in Induction Therapy for Patients With Active Ulcerative Colitis[J].Gastroenterology,2015,149(7):1775-1783.e2.
• [29]BERNS M,HOMMES D W.Anti-TNF-α therapies for the treatment of Crohn's disease:the past,present and future[J].Expert Opin Investig Drugs,2016,25(2):129-143.
• [30]BEHZADI P,BEHZADI E,RANJBAR R.IL-12 Family Cytokines:General Characteristics,Pathogenic Microor-ganisms,Receptors,and Signalling Pathways[J].Acta Microbiol Immunol Hung,2016,63(1):1-25.
• [31]ABRAHAM C,CHO J H.Inflammatory bowel disease[J].N Engl J Med,2009,361(21):2066-2078.
• [32]FEAGAN B G,SANDBORN W J,GASINK C,et al.Ustekin-umab as Induction and Maintenance Therapy for Crohn's Disease[J].N Engl J Med,2016,375(20):1946-1960.
• [33]COLOMBEL J F,SANDBORN W J,REINISCH W,et al.Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis[J].Aliment Pharmacol Ther,2018,47(2):219-228.
• [34]SANDS B E,CHEN J,FEAGAN B G,et al.Efficacy and Safety of MEDI2070,an Antibody Against Interleukin 23,in Patients With Moderate to Severe Crohn's Disease:A Phase 2a Study[J].Gastroenterology,2017,153(1):77-86.e6.
• [35]FEAGAN B G,SANDBORN W J,D'HAENS G,et al.Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease:a randomised,double-blind,placebo-controlled phase 2 study[J].Lancet,2017,389(10080):1699-1709.
• [36]SANDBORN W J,MARC,F,BHANDARI B R,et al.882-efficacy and safety of anti-interleukin-23 therapy with mirikizumab (ly3074828) in patients with moderate-to-severe ulcerative colitis in a phase 2 study[J].Gastroenterology,2018,154(6):S-1360-S-1361.
• [37]D'HAENS G G R,SANDBORN W J,FERRANTE M,et al.OP38 Maintenance treatment with mirikizumab,a p19-directed IL-23 antibody:52-week results in patients with moderately-to-severely active ulcerative colitis[J]//A SPECIAL MEETING REVIEW EDITION:Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO:A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO).Gastroenterol Hepatol (N Y),2019,15(5 Suppl 2):1-24.
• [38]MA C,JAIRATH V,KHANNA R.Investigational drugs in phase Ⅰ and phase Ⅱ clinical trials targeting interleukin 23 (IL23)for the treatment of Crohn's disease[J].Expert Opin Investig Drugs,2018,27(8):649-660.
• [39]DANESE S,RUDZI?SKI J,BRANDT W,et al.Tralokinumab for moderate-to-severe UC:a randomised,double-blind,placebo-controlled,phase Ⅱa study[J].Gut,2015,64(2):243-249.
• [40]REINISCH W,PANéS J,KHURANA S,et al.Anrukinzumab,an anti-interleukin 13 monoclonal antibody,in active UC:efficacy and safety from a phase IIa randomised multicentre study[J].Gut,2015,64(6):894-900.
• [41]HUEBER W,SANDS B E,LEWITZKY S,et al.Secukinumab,a human anti-IL-17A monoclonal antibody,for moderate to severe Crohn's disease:unexpected results of a randomised,double-blind placebo-controlled trial[J].Gut,2012,61(12):1693-1700.
• [42]HERRLINGER K R,DICULESCU M,FELLERMANN K,et al.Efficacy,safety and tolerability of vidofludimus in patients with inflammatory bowel disease:the ENTRANCE study[J].J Crohns Colitis,2013,7(8):636-643.
• [43]FEAGAN B G,GREENBERG G R,WILD G,et al.Treatment of ulcerative colitis with a humanized antibody to the alpha-4beta7 integrin[J].N Engl J Med,2005,352(24):2499-2507.
• [44]LAM M C,BRESSLER B.Vedolizumab for ulcerative colitis and Crohn's disease:results and implications of GEMINI studies[J].Immunotherapy,2014,6(9):963-971.
• [45]ARIJS I,DE HERTOGH G,LEMMENS B,et al.Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC[J].Gut,2018,67(1):43-52.
• [46]FEAGAN B G,RUTGEERTS P,SANDS B E,et al.Vedoliz-umab as induction and maintenance therapy for ulcerative colitis[J].N Engl J Med,2013,369(8):699-710.
• [47]SANDS B E,PEYRIN-BIROULET L,LOFTUS E V,et al.Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis[J].N Eng J Med,2019,381(13):1215-1226.
• [48]PAN W J,GRAHAM R S,ANDREWS J M,et al.Sa1207 Pharmacokinetics/Pharmacodynamics (PK/PD),Efficacy,and Safety of AMG 181 in Subjects With Active,Mild to Moderate Ulcerative Colitis-An Initial Assessment[J].Gastroenterology,2013,144(5):S-230.
• [49]SANDBORN W J,CYRILLE M,HANSEN M B,et al.Efficacy and Safety of Abrilumab in a Randomized,Placebo-Controlled Trial for Moderate to Severe Ulcerative Colitis[J].Gastroenterology,2019,156(4):946-957.e18.
• [50]SANDS B E,FEAGAN B G,SANDBORN W J,et al.Mongersen (GED-0301) for Active Crohn's Disease:Results of a Phase 3 Study[J].Am J Gastroenterol,2020,115(5):738-745.
• [51]FEAGAN B G,SANDS B E,ROSSITER G,et al.Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease[J].Gastroenterology,2017:S0016508517360687.
• [52]MONTELEONE G,DI SABATINO A,ARDIZZONE S,et al.Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301),an oral Smad7 antisense oligonucl-eotide,in active Crohn's disease[J].Aliment Pharmacol Ther,2016,43(6):717-724.
• [53]SANDS B E,FEAGAN B G,SANDBORN W J,et al.Mongersen (GED-0301) for Active Crohn's Disease:Results of a Phase 3 Study[J].Am J Gastroenterol,2020,115(5):738-745.
• [54]D'AMICO F,PEYRIN-BIROULET L,DANESE S,et al.New drugs in the pipeline for the treatment of inflammatory bowel diseases:what is coming?[J].Curr Opin Pharmacol,2020,55:141-150.
• [55]YOSHIMURA N,WATANABE M,MOTOYA S,et al.Safety and Efficacy of AJM300,an Oral Antagonist of α4 Integrin,in Induction Therapy for Patients With Active Ulcerative Colitis[J].Gastroenterology,2015,149(7):1775-1783.e2.
• [56]MASAKAZU T,MAMORU W,TAKAAKI K,et al.S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease-A Randomized,Double-Blind,Placebo-Controlled Trial[J].Gastroenterology,2009,136(5):A-181-A-181.
• [57]Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis.NCT02895100[Z].[2021-05-17].https://clinicaltrials.gov/ct2/show/record/NCT02895100.
• [58]SANDS B E,SANDBORN W J,FEAGAN B G,et al.Peficitinib,an Oral Janus Kinase Inhibitor,in Moderate-to-severe Ulcerative Colitis:Results From a Randomized,Phase 2 Study[J].J Crohns Colitis,2018,12(10):1158-1169.
• [59]FERRANTE M,SABINO J.Efficacy of JAK inhibitors in Ulcerative Colitis[J].J Crohns Colitis,2020,14(Supple-ment_2):S737-S745.
• [60]SANDBORN W J,SU C,PANES J.Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis[J].N Engl J Med,2017,377(5):496-497.
• [61]SANDBORN W J,SU C,SANDS B E,et al.Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis[J].N Engl J Med,2017,376(18):1723-1736.
• [62]VARYANI F,ARGYRIOU K,PHILLIPS F,et al.Profile of Tofacitinib in the Treatment of Ulcerative Colitis:An Evidence-Based Review of Recent Data[J].Drug Des Devel Ther,2019,13:4091-4105.
• [63]MA C,BATTAT R,DULAI P S,et al.Innovations in Oral Therapies for Inflammatory Bowel Disease[J].Drugs,2019,79(12):1321-1335.
• [64]D'AMICO F,FIORINO G,FURFARO F,et al.Janus kinase inhibitors for the treatment of inflammatory bowel diseases:deve-lopments from phaseⅠand phaseⅡclinical trials[J].Expert Opin Investig Drugs,2018,27(7):595-599.
• [65]VERMEIRE S,SCHREIBER S,PETRYKA R,et al.Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study):results from a phase 2,double-blind,randomised,placebo-controlled trial[J].Lancet,2017,389(10066):266-275.
• [66]ROGLER G.Efficacy of JAK inhibitors in Crohn's Disease[J].J Crohns Colitis,2020,14(Supplement_2):S746-S754.
• [67]SANDBORN W J,FEAGAN B G,PANES J,et al.Safety and Efficacy of ABT-494 (Upadacitinib),an Oral Jak1 Inhibitor,as Induction Therapy in Patients with Crohn's Disease:Results from Celest[J].Gastroenterology,2017,152(5):S1308-S1309.
• [68]HIGGINS P,HéBUTERNE X,SIFFLEDEEN J,et al.Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately-to-Severely Active Ulcerative Colitis:Combined Results From 382 Subjects in the Phase 2b Study U-ACHIEVE[J].Am J Gastroenterol,2019,114(Supplement):S131.
• [69]SANDBORN W J,PEYRIN-BIROULET L,ZHANG J K,et al.Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis[J].Gastroenterology,2019:S0016508519415266.
• [70]Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis (ELEVATE UC 12).NCT03996369[Z].[2021-05-17].https://clinicaltrials.gov/ct2/show/NCT03996369.
• [71]VERMEIRE S,CHIOREAN M,PANéS J,et al.Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis:Results from the Open-label Extension of the OASIS Study[J].J Crohns Colitis,2021.Online ahead of print.
• [72]SANDS B E,COLOMBEL J F,HA C,et al.Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Manage-ment[J].Inflammatory Bowel Diseases,2020.Epub ahead of print.
• [73]FEAGAN B G,SANDBORN W J,DANESE S,et al.Ozanimod induction therapy for patients with moderate to severe Crohn's disease:a single-arm,phase 2,prospective observer-blinded endpoint study[J].Lancet Gastroenterol Hepatol,2020,5(9):819-828.
• [74]D'HAENS G,SANDBORN W J,COLOMBEL J F,et al.A phase Ⅱ study of laquinimod in Crohn's disease[J].Gut,2015,64:1227-1235.
• [75]Extension Study of MT-1303 in Subjects With Crohn's Disease.NCT02389790[Z].[2021-05-17].https://clinicaltrials.gov/ct2/show/NCT02389790.
• [76]THEISS A L.Sphingosine-1-phosphate:Driver of NFκB and STAT3 persistent activation in chronic intestinal inflammation and colitis-associated cancer[J].JAKSTAT,2013,2(3):e24150.
• [77]ASTHANA A K,SPARROW M P,PEYRIN-BIROULET L.Optimizing conventional medical therapies in inflammatory bowel disease in 2014[J].Curr Drug Targets,2014,15(11):1002-1010.